- Home
- BMEA vs ZURA Comparison
BMEA vs ZURA Comparison
Compare BMEA & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- ZURA
- Stock Information
- Founded
- BMEA 2017
- ZURA 2022
- Country
- BMEA United States
- ZURA United States
- Employees
- BMEA N/A
- ZURA N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BMEA Health Care
- ZURA Health Care
- Exchange
- BMEA Nasdaq
- ZURA Nasdaq
- Market Cap
- BMEA 65.8M
- ZURA 61.9M
- IPO Year
- BMEA 2021
- ZURA N/A
- Fundamental
- Price
- BMEA $1.81
- ZURA $1.13
- Analyst Decision
- BMEA Strong Buy
- ZURA Buy
- Analyst Count
- BMEA 10
- ZURA 7
- Target Price
- BMEA $22.30
- ZURA $14.33
- AVG Volume (30 Days)
- BMEA 5.2M
- ZURA 545.9K
- Earning Date
- BMEA 07-30-2025
- ZURA 08-08-2025
- Dividend Yield
- BMEA N/A
- ZURA N/A
- EPS Growth
- BMEA N/A
- ZURA N/A
- EPS
- BMEA N/A
- ZURA N/A
- Revenue
- BMEA N/A
- ZURA N/A
- Revenue This Year
- BMEA N/A
- ZURA N/A
- Revenue Next Year
- BMEA N/A
- ZURA N/A
- P/E Ratio
- BMEA N/A
- ZURA N/A
- Revenue Growth
- BMEA N/A
- ZURA N/A
- 52 Week Low
- BMEA $1.29
- ZURA $0.97
- 52 Week High
- BMEA $13.07
- ZURA $5.07
- Technical
- Relative Strength Index (RSI)
- BMEA 44.35
- ZURA 45.37
- Support Level
- BMEA $2.24
- ZURA $1.10
- Resistance Level
- BMEA $3.08
- ZURA $1.37
- Average True Range (ATR)
- BMEA 0.40
- ZURA 0.09
- MACD
- BMEA -0.03
- ZURA 0.00
- Stochastic Oscillator
- BMEA 25.07
- ZURA 37.18
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.